AU Patent

AU2013202360B2 — Methods of treatment using single doses of oritavancin

Assigned to Melinta Subsidiary Corp · Expires 2016-03-24 · 10y expired

What this patent protects

METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including …

USPTO Abstract

METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013202360B2
Jurisdiction
AU
Classification
—
Expires
2016-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Melinta Subsidiary Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.